Open-House-Biologika-Rabattverträge 2026-13 - Romiplostim

Summary

The tender concerns discount agreements for the active substance romiplostim under an open-house biologics procedure. It is a supplies contract open to all suitable pharmaceutical companies on uniform terms. There are no individual negotiations and no exclusivity. The contract term is up to 24 months from 01/07/2026, but no later than 30/06/2028. To participate, the bidder must show that it is a pharmaceutical undertaking, holds a valid authorisation and meets the reliability requirements.